Indices of sympathetic activity and the paradox of chromogranin A

Journal of Hypertension

Volumn 28, Issue 4, 2010, Pages 676-678

  Lambert, Gavin ^a   Grassi, Guido ^b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b SAN GERARDO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYPHENYLETHYLENE GLYCOL; AROMATIC LEVO AMINO ACID DECARBOXYLASE; CATECHOLAMINE; CATESTATIN; CHROMOGRANIN A; DOPAMINE BETA MONOOXYGENASE; NEUROPEPTIDE Y; NEUROTRANSMITTER; NORADRENALIN; NORADRENALIN TRANSPORTER; PANCREASTATIN; PROTEIN PRECURSOR; STATIN; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; VASOSTATIN;

ADRENAL GLAND; CATECHOLAMINE METABOLISM; CATECHOLAMINE RELEASE; ENZYME ACTIVITY; GENE DOSAGE; HEART FAILURE; ISOTOPE DILUTION ASSAY; KNOCKOUT MOUSE; MICRODIALYSIS; NEUROTRANSMITTER RELEASE; NONHUMAN; NORADRENALIN BLOOD LEVEL; NORADRENALIN URINE LEVEL; NOTE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYMPATHETIC NERVE; SYMPATHETIC TONE;

EID: 78650782559     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32833857e3     Document Type: Note

References (42)

1. Esler M, Jennings G, Lambert G, Meredith I, Horne M, Eisenhofer G. Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions. Physiol Rev 1990; 70:963-985.
2. von Euler US. A specific sympathetic ergone in adrenergic nerve fibres (sympathin) and its relation to adrenaline and noradrenaline. Acta Physiol Scand 1946; 12:73-97.
3. Brown GL, Gillespie JS. The output of sympathetic transmitter from the spleen of the cat. J Physiol 1957; 138:81-102.
4. DeQuattro V, Miura Y, Lurvey A, Cosgrove M, Mendez R. Increased plasma catecholamine concentrations and vas deferens norepinephrine biosynthesis in men with elevated blood pressure. Circ Res 1975; 36:118-126.
5. Weinshilboum RM, Raymond FA, Elveback LR, Weidman WH. Serum dopamine-beta-hydroxylase activity: sibling-sibling correlation. Science 1973; 181 :943-945.
6. Chidsey CA, Braunwald E, Morrow AG, Mason DT. Myocardial norepinephrine concentration in man: effects of reserpine and of congestive heart failure. N Engl J Med 1963; 269:653-658.
7. Engelman K, Portnoy B, Lovenberg W. A sensitive and specific doubleisotope derivative method for the determination of catecholamines in biological specimens. Am J Med Sci 1968; 255:259-268.
8. Zweifler AJ, Julius S. Increased platelet catecholamine content in pheochromocytoma: a diagnostic test in patients with elevated plasma catecholamines. N Engl J Med 1982; 306:890-894.
9. von Euler US, Hellner S, Purkhold A. Excretion of noradrenaline in the urine in hypertension. Scand J Clin Lab Invest 1954; 6:54-59.
10. Eisenhofer G, Goldstein DS, Ropchak TG, Nguyen HQ, Keiser HR, Kopin IJ. Source and physiological significance of plasma 3,4- dihydroxyphenylglycol and 3-methoxy-4-hydroxyphenylglycol. J Auton Nerv Syst 1988; 24:1-14.
11. Esler M, Jackman G, Bobik A, Kelleher D, Jennings G, Leonard P, et al. Determination of norepinephrine apparent release rate and clearance in humans. Life Sci 1979; 25:1461-1470.
12. Khan MH, Sinoway LI, MacLean DA. Effects ofgraded LBNP on MSNA and interstitial norepinephrine. Am J Physiol Heart Circ Physiol 2002; 283:H2038-H2044.
13. Morris MJ, Russell AE, Kapoor V, Cain MD, Elliott JM, West MJ, et al. Increases in plasma neuropeptide Y concentrations during sympathetic activation in man. J Auton Nerv Syst 1986; 17:143-149.
14. Morris MJ, CoxHS, Lambert GW, Kaye DM, Jennings GL, Meredith IT, et al. Region-specific neuropeptide Y overflows at rest and during sympathetic activation in humans. Hypertension 1997; 29:137-143.
15. O'Connor DT, Bernstein KN. Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromocytoma. N Engl J Med 1984; 311 :764-770.
16. Eisenhofer G, Esler MD, Meredith IT, Dart A, Cannon ROd, Quyyumi AA, et al. Sympathetic nervous function in human heart as assessed by cardiac spillovers of dihydroxyphenylglycol and norepinephrine. Circulation 1992; 85:1775-1785.
17. Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence ofincreased overall and cardiorenal sympathetic nervous activity. Circulation 1986; 73:615-621.
18. Lambert GW, Kaye DM, Lefkovits J, Jennings GL, Turner AG, Cox HS, et al. Increased central nervous system monoamine neurotransmitter turnover and its association with sympathetic nervous activity in treated heart failure patients. Circulation 1995; 92:1813-1818.
19. Grassi G, Colombo M, Seravalle G, Spaziani D, Mancia G. Dissociation between muscle and skin sympathetic nerve activity in essential hypertension, obesity, and congestive heart failure. Hypertension 1998; 31 :64-67.
20. Grassi G, Seravalle G, Quarti-Trevano F, Dell'Oro R. Sympathetic activation in congestive heart failure: evidence, consequences and therapeutic implications. Curr Vasc Pharmacol 2009; 7:137-145.
21. Chidsey CA, Braunwald E. Sympathetic activity and neurotransmitter depletion in congestive heart failure. Pharmacol Rev 1966; 18:685-700.
22. Eisenhofer G, Friberg P, Rundqvist B, Quyyumi AA, Lambert G, Kaye DM, et al. Cardiac sympathetic nerve function in congestive heart failure. Circulation 1996; 93:1667-1676.
23. O'Connor DT, Klein RL, Thureson-Klein AK, Barbosa JA. Chromogranin A: localization and stoichiometry in large dense core catecholamine storage vesicles from sympathetic nerve.. Brain Res 1991; 567:188-196.
24. Dimsdale JE, O'Connor DT, Ziegler M, Mills P. Chromogranin A correlates with norepinephrine release rate. Life Sci 1992; 51 :519-525.
25. Jansson AM, Rosjo H, Omland T, Karlsson T, Hartford M, Flyvbjerg A, et al. Prognostic value of circulating chromogranin A levels in acute coronary syndromes. Eur Heart J 2009; 30:25-32.
26. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 1995; 26:1257-1263.
27. Petersson M, Friberg P, Eisenhofer G, Lambert G, Rundqvist B. Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure. Eur Heart J 2005; 26:906-913. (Pubitemid 40676571)
28. Kaye DM, Lefkovits J, Cox H, Lambert G, Jennings G, Turner A, et al. Regional epinephrine kinetics in human heart failure: evidence for extra- adrenal, nonneural release. Am J Physiol 1995; 269:H182-188.
29. Esler M, Jennings G, Korner P, Willett I, Dudley F, Hasking G, et al. Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension 1988; 11:3-20.
30. O'Connor DT. Chromogranin A: implications for hypertension. J Hypertens Suppl 1984; 2:S147-150.
31. Takiyyuddin MA, Parmer RJ, Kailasam MT, Cervenka JH, Kennedy B, Ziegler MG, et al. Chromogranin A in human hypertension. Influence of heredity. Hypertension 1995; 26:213-220.
32. Mahapatra NR, O'Connor DT, Vaingankar SM, Hikim AP, Mahata M, Ray S, et al. Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. J Clin Invest 2005; 115:1942-1952.
33. Vaingankar SM, Li Y, Gayen J, Choksi S, Rao F, Ziegler MG, et al. Effects of chromograninA deficiency and excess in vivo: biphasic blood pressure and catecholamine responses. J Hypertens 2010; 28: 817-825.
34. Kim T, Tao-Cheng JH, Eiden LE, Loh YP. Chromogranin A, an 'on/off' switch controlling dense-core secretory granule biogenesis. Cell 2001; 106:499-509.
35. Videen JS, Mezger MS, Chang YM, O'Connor DT. Calcium and catecholamine interactions with adrenal chromogranins. Comparison of driving forces in binding and aggregation. J Biol Chem 1992; 267:3066-3073.
36. Montesinos MS, Machado JD, Camacho M, Diaz J, Morales YG, Alvarez de la Rosa D, et al. The crucial role ofchromogranins in storage and exocytosis revealed using chromaffin cells from chromogranin A null mouse. J Neurosci 2008; 28:3350-3358.
37. Taupenot L, Harper KL, O'Connor DT. The chromogranin -secretogranin family. N Engl J Med 2003; 348:1134-1149.
38. Simon JP, Bader MF, Aunis D. Secretion from chromaffin cells is controlled by chromogranin A-derived peptides. Proc Natl Acad Sci U S A 1988; 85:1712-1716.
39. Mahata SK, O'Connor DT, Mahata M, Yoo SH, Taupenot L, Wu H, et al. Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest 1997; 100:1623-1633.
40. Rao F, Wen G, Gayen JR, Das M, Vaingankar SM, Rana BK, et al. Catecholamine release-inhibitory peptide catestatin (chromogranin A(352-372)): naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertension. Circulation 2007; 115:2271-2281.
41. O'Connor DT, Kailasam MT, Kennedy BP, Ziegler MG, Yanaihara N, Parmer RJ. Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. J Hypertens 2002; 20:1335-1345.
42. Ferrier C, Cox H, Esler M. Elevated total body noradrenaline spillover in normotensive members of hypertensive families. Clin Sci (Lond) 1993; 84:225-230.